


## PHARMACEUTICAL 2023

## NEXIEN BIOPHARMA INC. Rank 438 of 446







## PHARMACEUTICAL 2023

## NEXIEN BIOPHARMA INC. Rank 438 of 446

The relative strengths and weaknesses of NEXIEN BIOPHARMA INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of NEXIEN BIOPHARMA INC. compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 75% points. The greatest weakness of NEXIEN BIOPHARMA INC. is the variable Assets, Current, reducing the Economic Capital Ratio by 285% points.

The company's Economic Capital Ratio, given in the ranking table, is -452%, being 495% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	125
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	242
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	33
Other Liabilities	0
Other Net Income	-62
Other Revenues	0
Property and Equipment	0
Research and Development	0
Selling, General and Administrative Expense	531

Output Variable	Value in 1000 USD
Assets	125
Liabilities	242
Expenses	564
Revenues	0
Stockholders Equity	-118
Net Income	-626
Comprehensive Net Income	-626
Economic Capital Ratio	-452%

